Brief: Chiome Bioscience says execution of collaborative development license and exclusive option agreement for anti-Semaphorin 3A antibody
22/03/2018 06:43
March 22(Reuters) - Chiome Bioscience Inc 4583.T
* Says it has executed a collaborative development license
and
exclusive option agreement with SemaThera Inc. for
anti-Semaphorin 3A antibody for the development of therapeutics
and diagnostics in Diabetic Macular Edema (DME) and other
diabetic complications including non-ocular diseases
Source text in Japanese:https://goo.gl/DkP1Px
Further company coverage: 4583.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))